劉筠

摘要：目的? 探討異環(huán)磷酰胺與依托泊苷聯(lián)合治療復(fù)發(fā)卵巢癌的臨床效果。方法? 選取2018年1月～2019年2月我院收治的復(fù)發(fā)卵巢癌患者90例，按照隨機(jī)數(shù)字表法分為對(duì)照組和觀察組，各45例。對(duì)照組采用依托泊苷治療，觀察組在對(duì)照組基礎(chǔ)上聯(lián)合異環(huán)磷酰胺治療，比較兩組化療后的效果和CA125值的變化。結(jié)果? 觀察組CA125、CA125Ⅱ值均低于對(duì)照組[（55.62±3.25）U/ml vs（68.42±3.25）U/ml ]、[（53.62±2.25）U/ml vs（61.42±5.25）U/ml ]，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。觀察組臨床總有效率為95.55%，高于對(duì)照組的71.11%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論? 異環(huán)磷酰胺與依托泊苷聯(lián)合治療復(fù)發(fā)卵巢癌可較快降低腫瘤負(fù)荷、減輕相關(guān)癥狀，具有較高的臨床應(yīng)用價(jià)值。

關(guān)鍵詞：復(fù)發(fā)卵巢癌癥;異環(huán)磷酰胺;依托泊苷;化療

中圖分類號(hào)：R587.1? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 文獻(xiàn)標(biāo)識(shí)碼：A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? DOI：10.3969/j.issn.1006-1959.2019.13.044

文章編號(hào)：1006-1959（2019）13-0143-02

Abstract：Objective? To investigate the clinical effect of combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer. Methods? 90 patients with recurrent ovarian cancer admitted to our hospital from January 2018 to February 2019 were enrolled. According to the random number table， they were divided into control group and observation group， with 45 cases in each group. The control group was treated with etoposide. The observation group was given combination therapy with ifosfamide and etoposide. The effects of chemotherapy and CA125 values were compared between the two groups. Results? The values of CA125 and CA125Ⅱ in the observation group were lower than those in the control group [（55.62±3.25）U/ml? vs （68.42±3.25）U/ml ]， [（53.62±2.25）U/ml? vs （61.42±5.25）U/ml ]，the difference was statistically significant （P<0.05）. The total effective rate of the observation group was 95.55%， which was higher than that of the control group 71.11%，the difference was statistically significant （P<0.05）.Conclusion? The combination of ifosfamide and etoposide in the treatment of recurrent ovarian cancer is effective， and the recovery time is short， which has high clinical value.

Key words：Recurrent ovarian cancer;Ifosfamide;Etoposide;Chemotherapy

復(fù)發(fā)卵巢癌（ovariancancer）是指經(jīng)過腫瘤細(xì)胞的減滅和正規(guī)足量的化療后達(dá)到臨床完全緩解，停藥半年后臨床再次出現(xiàn)腫瘤復(fù)發(fā)的現(xiàn)象，是婦科常見的惡性腫瘤。復(fù)發(fā)卵巢癌的發(fā)病因素復(fù)雜，隨著人們生活水平的提高，飲食結(jié)構(gòu)改變，加之社會(huì)關(guān)系、遺傳因素、工作方式等，導(dǎo)致復(fù)發(fā)卵巢癌癥病率逐年增加。異環(huán)磷酰胺與依托泊苷聯(lián)合治療復(fù)發(fā)卵巢癌具有創(chuàng)傷小、出血量少、術(shù)后并發(fā)癥少等優(yōu)點(diǎn)[1]。本文主要探討異環(huán)磷酰胺與依托泊苷聯(lián)合治療復(fù)發(fā)卵巢癌的臨床效果，現(xiàn)報(bào)道如下。

1資料與方法

1.1一般資料? 選擇2018年1月～2019年2月天津市中心婦產(chǎn)科醫(yī)院收治的復(fù)發(fā)卵巢癌患者90例，按照隨機(jī)數(shù)字表法分為對(duì)照組和觀察組，各45例。對(duì)照組年齡31～45歲，平均年齡（38.00±2.53）歲，病程6 d～2年，平均病程（1.05±0.42）年。觀察組年齡32～46歲，平均年齡（39.00±2.37）歲，病程7 d～2年，平均病程（1.09±0.45）年。兩組年齡、病程等一般資料比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05），具有可比性。本研究經(jīng)醫(yī)院倫理委員會(huì)審批通過，患者及家屬知情同意并簽署知情同意書。